Rockefeller Capital Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$17.8M Buy
124,926
+1,138
+0.9% +$173K 0.03% 542
2026
Q2
$19.4M Buy
123,788
+5,481
+5% +$822K 0.03% 495
2026
Q1
$18.1M Buy
118,307
+10,102
+9% +$1.55M 0.03% 468
2025
Q4
$14.9M Buy
108,205
+5,526
+5% +$724K 0.03% 518
2025
Q3
$13.2M Buy
102,679
+4,936
+5% +$602K 0.03% 549
2025
Q2
$11.8M Sell
97,743
-3,920
-4% -$442K 0.03% 564
2025
Q1
$11.3M Sell
101,663
-6,139
-6% -$654K 0.03% 536
2024
Q4
$10.5M Buy
107,802
+2,189
+2% +$233K 0.03% 544
2024
Q3
$12.1M Sell
105,613
-4,910
-4% -$557K 0.03% 484
2024
Q2
$11.8M Sell
110,523
-38,218
-26% -$3.84M 0.03% 460
2024
Q1
$14.4M Buy
148,741
+46,960
+46% +$4.81M 0.04% 412
2023
Q4
$10.3M Sell
101,781
-24,750
-20% -$2.39M 0.03% 450
2023
Q3
$12.9M Sell
126,531
-70,296
-36% -$7.14M 0.05% 357
2023
Q2
$19.8M Buy
196,827
+3,918
+2% +$392K 0.08% 269
2023
Q1
$17.7M Sell
192,909
-20,676
-10% -$1.81M 0.08% 291
2022
Q4
$19.4M Sell
213,585
-243
-0.1% -$20.5K 0.1% 236
2022
Q3
$16.3M Sell
213,828
-525
-0.2% -$43.5K 0.08% 256
2022
Q2
$18.1M Buy
214,353
+13,074
+6% +$1.15M 0.1% 221
2022
Q1
$17.7M Sell
201,279
-22,266
-10% -$1.93M 0.09% 246
2021
Q4
$19.6M Buy
223,545
+13,505
+6% +$1.12M 0.09% 224
2021
Q3
$17.2M Buy
210,040
+9,174
+5% +$825K 0.09% 235
2021
Q2
$18.3M Buy
200,866
+67,553
+51% +$6.02M 0.1% 218
2021
Q1
$11.4M Buy
133,313
+29,186
+28% +$2.62M 0.08% 241
2020
Q4
$9.8M Sell
104,127
-47,264
-31% -$4.13M 0.07% 228
2020
Q3
$13.2M Sell
151,391
-740,514
-83% -$64.2M 0.12% 169
2020
Q2
$77.9M Sell
891,905
-277,255
-24% -$23.9M 0.82% 22
2020
Q1
$96.4M Sell
1,169,160
-70,193
-6% -$6.26M 1.26% 16
2019
Q4
$117M Sell
1,239,353
-18,723
-1% -$1.68M 1.46% 13
2019
Q3
$109M Buy
1,258,076
+9,133
+0.7% +$820K 1.48% 15
2019
Q2
$114M Sell
1,248,943
-12,126
-1% -$1.03M 1.59% 15
2019
Q1
$121M Buy
1,261,069
+9,640
+0.8% +$864K 1.73% 16
2018
Q4
$107M Buy
1,251,429
+39,244
+3% +$3.41M 1.88% 16
2018
Q3
$104M Buy
1,212,185
+222,141
+22% +$18.3M 1.59% 21
2018
Q2
$74.8M Sell
990,044
-13,035
-1% -$1M 1.22% 28
2018
Q1
$81.1M Sell
1,003,079
-3,243
-0.3% -$276K 1.34% 23
2017
Q4
$84.5M Sell
1,006,322
-50,324
-5% -$4.24M 1.33% 27
2017
Q3
$90.7M Sell
1,056,646
-4,041
-0.4% -$341K 1.73% 17
2017
Q2
$88.5M Sell
1,060,687
-3,630
-0.3% -$287K 1.76% 19
2017
Q1
$79M Sell
1,064,317
-8,577
-0.8% -$638K 1.58% 23
2016
Q4
$78.2M Sell
1,072,894
-7,613
-0.7% -$551K 1.59% 24
2016
Q3
$85.3M Sell
1,080,507
-65,564
-6% -$5.33M 1.78% 21
2016
Q2
$94.6M Sell
1,146,071
-9,923
-0.9% -$765K 1.89% 19
2016
Q1
$83.7M Sell
1,155,994
-4,922
-0.4% -$374K 1.63% 26
2015
Q4
$100M Sell
1,160,916
-5,193
-0.4% -$460K 1.94% 13
2015
Q3
$107M Buy
1,166,109
+21,449
+2% +$2.13M 2.18% 9
2015
Q2
$113M Buy
1,144,660
+23,466
+2% +$2.4M 2.33% 8
2015
Q1
$111M Sell
1,121,194
-16,795
-1% -$1.66M 2.39% 9
2014
Q4
$105M Sell
1,137,989
-16,538
-1% -$1.53M 2.31% 11
2014
Q3
$109M Buy
1,154,527
+57,682
+5% +$5.21M 2.42% 6
2014
Q2
$99.3M Buy
1,096,845
+21,152
+2% +$1.86M 2.23% 7
2014
Q1
$91.5M Buy
1,075,693
+36,352
+3% +$2.96M 1.98% 9
2013
Q4
$83.5M Buy
1,039,341
+57,680
+6% +$4.47M 1.81% 9
2013
Q3
$75.3M Buy
981,661
+23,126
+2% +$1.71M 1.75% 11
2013
Q2
$67.8M Hold
958,535
– – 1.62% 14

Other funds holding NVS

Rockefeller Capital Management's NVS Position: Q3 2026 in Review

Rockefeller Capital Management increased its Novartis (NVS) stake by 0.92% in Q3 2026, buying an estimated $173K and bringing the position to 124,926 shares worth $17.8M. The position accounts for 0.03% of the portfolio, ranked #542.

Rockefeller Capital Management first reported a position in NVS in Q2 2013 and has held it in 54 quarters since. The position peaked at $121M in Q1 2019. 1,560 funds tracked by Wall St. Rank hold NVS as of Q3 2026.

  • Rockefeller Capital Management held 124,926 shares of Novartis worth $17.8M as of Q3 2026.
  • Rockefeller Capital Management bought 1,138 Novartis shares in Q3 2026, an estimated $173K.
  • Novartis made up 0.03% of Rockefeller Capital Management's portfolio in Q3 2026, its #542 holding.
  • Rockefeller Capital Management first reported a position in Novartis in Q2 2013 and has held it in 54 quarters since.
  • Rockefeller Capital Management's Novartis position peaked at $121M in Q1 2019.
  • 1,560 funds tracked by Wall St. Rank held Novartis as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.